▲ bullish
Impact
PhasePivotal (registrational)
Time to marketIf the 1H 2027 pivotal data and FDA feedback are positive, a BLA submission could follow in 2027-2028, with potential approval in 2028-2029. This timeline depends on the regulatory pathway the FDA outlines.
TSHA-102 Updated Nov 13
What to watch
The next major binary catalyst is the topline 6-month interim analysis from the REVEAL pivotal trial and FDA feedback on the BLA submission pathway, both expected in the first half of 2027. Positive data and regulatory alignment could open a clear path to approval and drive significant upside; negative data or FDA pushback would be a severe setback for this single-asset company.
Bull case
- TSHA-102 has shown broad, multi-domain functional improvement that deepened over time through 12+ months in REVEAL Part A, regardless of age or disease severity.
- The drug has been generally well-tolerated with no treatment-related serious adverse events or dose-limiting toxicities across the REVEAL Phase 1/2 and pivotal trials.
- Multiple FDA regulatory designations (Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease) signal agency interest and could accelerate the BLA pathway.
Bear case
- Single-asset risk: TSHA-102 is Taysha's only clinical-stage program; any clinical setback would devastate the stock.
- Competition from Neurogene's NGN-401, which also has FDA Breakthrough Therapy designation and is in a registrational trial (EMBOLDEN) with topline data expected in 2H 2027, could split the Rett syndrome gene therapy market.
- Elevated short-sale volume: the 20-session short-sale ratio of 63.75% is above the ticker's own baseline of 54.85% (z-score 1.58), indicating elevated bearish positioning.